DelveInsight’s “Warm Autoimmune Hemolytic Anemia (WAIHA) Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Warm Autoimmune Hemolytic Anemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Warm Autoimmune Hemolytic Anemia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Key highlights of the WAIHA Market Report:
In 2023, the total market size for warm autoimmune hemolytic anemia (wAIHA) in the 7MM was approximately USD 300 million. wAIHA is the most prevalent form of autoimmune hemolytic anemia, accounting for about 70–80% of adult cases and 50% of pediatric cases. While wAIHA can develop at any age, the median age of onset is 52 years.
The primary treatment for wAIHA is corticosteroids, which remain the standard first-line therapy. If corticosteroids are ineffective, splenectomy may be considered as an alternative. Rituximab has emerged as a viable option for cases resistant to conventional treatments, and immunosuppressive medications are often used to manage chronic, severe, or refractory cases. Drugs like azathioprine, cyclophosphamide, and mycophenolate mofetil have proven useful adjuncts, particularly for chronic and refractory AIHA cases.
In cases of refractory or recurrent wAIHA, sequential treatment lines are typically employed. The challenges in managing wAIHA highlight the importance of advancing research into new therapeutic options. Innovative targeted therapies that address the disease’s underlying pathogenesis are urgently needed, as no approved treatments currently exist for wAIHA. Promising new treatments include B-cell and plasma-cell targeting agents, complement inhibitors, and therapies aimed at removing pathogenic autoantibodies through neonatal Fc receptor blockade.
Emerging agents like Obexelimab, Ianalumab, Nipocalimab, Rilzabrutinib, and Povetacicept have the potential to expand the therapeutic options available for wAIHA, particularly for patients whose disease relapses or is refractory to rituximab. These novel therapies may also address unmet needs in very acute cases.
With no licensed treatments currently available, the market for wAIHA presents a significant opportunity. The current standard of care is limited by decreasing drug effectiveness over time and the adverse effects that increase patient burden. New medications that gain approval could capture a substantial market share due to the lack of competition and the high demand for effective treatments.
Rituximab remains the leading treatment in the wAIHA market, both in terms of efficacy and familiarity. Among the new treatments, rilzabrutinib, an oral BTK inhibitor developed by Novartis/MorphoSys, stands out as a promising option for immune-mediated diseases like wAIHA.
Among the 7MM, the US accounted for the highest prevalent cases of autoimmune hemolytic anemia in 2023, with around 57,000 cases; these cases are expected to increase during the forecast period.
Among gender-specific prevalent cases of wAIHA, females stand out as major contributors. In 2023, Females accounted for up to 60% cases of wAIHA. These cases are anticipated to increase by 2034 in the US.
Amongst EU4 and the UK, the total prevalent cases of wAIHA were highest in Germany, while the lowest number of cases were in Spain in 2023.
According to the estimates, in Japan, it is observed that wAIHA was most prevalent in the =65 year’s age group, accounting for over 64% of total cases in 2023.
Warm Autoimmune Hemolytic Anemia (WAIHA) Overview
Warm Autoimmune Hemolytic Anemia (wAIHA) is a prevalent autoimmune disorder and is projected by the World Health Organization to become the leading cause of disease burden in high-income countries by 2034. Autoimmune hemolytic anemia (AIHA) is characterized by the premature destruction of red blood cells (RBCs) due to the presence of anti-RBC autoantibodies, with or without complement activation. These autoantibodies are produced by both tissue-resident and circulating self-reactive B lymphocytes, in collaboration with T-helper lymphocytes.
wAIHA is the most common form of autoimmune hemolytic anemia, accounting for approximately 70–80% of cases in adults and about 50% of cases in children. More than half of these cases are classified as primary, with no identified cause, while the remainder are secondary to conditions such as lymphoproliferative disorders, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma, or solid tumors.
Currently, there are no approved therapies specifically for wAIHA, and only about one-third of patients are able to maintain disease control after discontinuing steroid treatment.
Warm Autoimmune Hemolytic Anemia (WAIHA) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Warm Autoimmune Hemolytic Anemia market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Warm Autoimmune Hemolytic Anemia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Warm Autoimmune Hemolytic Anemia (WAIHA) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Warm Autoimmune Hemolytic Anemia (WAIHA) Epidemiology Segmented by –
Prevalent Cases of Autoimmune Hemolytic Anemia (AIHA) in the 7MM [2020-2034]
Diagnosed Prevalent Cases of Warm Autoimmune Hemolytic Anemia (wAIHA) in the 7MM [2020–2034]
Prevalent Cases of Warm Autoimmune Hemolytic Anemia (wAIHA) in the 7MM [2020–2034]
Gender-specific Diagnosed Prevalence of Warm Autoimmune Hemolytic Anemia (wAIHA) in the 7MM [2020–2034]
Type-specific Diagnosed Prevalent Cases of Warm Autoimmune Hemolytic Anemia (wAIHA) in the 7MM [2020–2034]
Warm Autoimmune Hemolytic Anemia (WAIHA) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the Warm Autoimmune Hemolytic Anemia market or expected to be launched during the study period. The analysis covers the Warm Autoimmune Hemolytic Anemia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Warm Autoimmune Hemolytic Anemia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Warm Autoimmune Hemolytic Anemia Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market
Warm Autoimmune Hemolytic Anemia (WAIHA) Therapeutics Analysis
There are several major pharma and biotech giants developing therapies for Warm Autoimmune Hemolytic Anemia. Rigel Pharmaceuticals, Immunovant Sciences GmbH, Apellis Pharmaceuticals are some of the leading companies in the therapeutics market with their Warm Autoimmune Hemolytic Anemia drug candidates in the mid to advanced stage of clinical development.
Leading Companies in the Warm Autoimmune Hemolytic Anemia (WAIHA) therapeutics market include:
Immunovant Sciences GmbH
Apellis Pharmaceuticals, Inc.
Bioverativ
Rigel Pharmaceuticals
Johnson & Johnson
Sanofi
Incyte Corporation
Annexon
Bioverativ, a Sanofi company
Warm Autoimmune Hemolytic Anemia (WAIHA) Drugs Covered in the Report Include:
Fostamatinib: Rigel Pharmaceuticals
BIV009: Bioverativ, a Sanofi company
Parsaclisib: Incyte Corporation
Rilzabrutinib: Sanofi
Nipocalimab: Johnson & Johnson
Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https://www.delveinsight.com/sample-request/warm-autoimmune-hemolytic-anemia-waiha-market
Table of Contents
1. Key Insights
2. Executive Summary
3. Warm Autoimmune Hemolytic Anemia Competitive Intelligence Analysis
4. Warm Autoimmune Hemolytic Anemia Market Overview at a Glance
5. Warm Autoimmune Hemolytic Anemia Disease Background and Overview
6. Warm Autoimmune Hemolytic Anemia Patient Journey
7. Warm Autoimmune Hemolytic Anemia Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Warm Autoimmune Hemolytic Anemia Treatment Algorithm, Current Treatment, and Medical Practices
9. Warm Autoimmune Hemolytic Anemia Unmet Needs
10. Key Endpoints of Warm Autoimmune Hemolytic Anemia Treatment
11. Warm Autoimmune Hemolytic Anemia Marketed Products
12. Warm Autoimmune Hemolytic Anemia Emerging Drugs and Latest Therapeutic Advances
13. Warm Autoimmune Hemolytic Anemia Seven Major Market Analysis
14. Attribute Analysis
15. Warm Autoimmune Hemolytic Anemia Market Outlook (In US, EU5, and Japan)
16. Warm Autoimmune Hemolytic Anemia Access and Reimbursement Overview
17. KOL Views on the Warm Autoimmune Hemolytic Anemia Market
18. Warm Autoimmune Hemolytic Anemia Market Drivers
19. Warm Autoimmune Hemolytic Anemia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Download our report @ https://www.delveinsight.com/report-store/warm-autoimmune-hemolytic-anemia-waiha-market
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
